Akèy › Timè Wilms › Texas
Etid klinik pou Timè Wilms nan Texas
6 etid pou Timè Wilms ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 29, 2026 · NCT04616560A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- ak 10 plis
Ap rekriteFaz 2
Jiska laj 30 · Tout sèks · Mizajou Aug 25, 2026 · NCT04322318Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Aug 6, 2026 · NCT04715191A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Cook Children's Health Care System (Data Collection Only), Fort Worth
Ap rekriteFaz 2
12 Months · Tout sèks · Mizajou May 6, 2026 · NCT05985161Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
- Houston Methodist Hospital, Houston
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Nov 3, 2025 · NCT06198296Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.